Appeals court: Federal biosimilars act preempts state law

In a ruling issued in the case of Amgen Inc. v. Sandoz Inc. concerning biosimilars, the U.S. Court of Appeals for the Federal Circuit (CAFC) held that the federal Biologics

Read the full 304 word article

User Sign In